Henry Schein (NASDAQ:HSIC) Issues FY 2026 Earnings Guidance

Henry Schein (NASDAQ:HSIC) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 5.230-5.370 for the period, compared to the consensus EPS estimate of 5.310. The company issued revenue guidance of $13.6 billion-$13.8 billion, compared to the consensus revenue estimate of $13.7 billion.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Wall Street Zen downgraded Henry Schein from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 26th. Citigroup initiated coverage on shares of Henry Schein in a research report on Wednesday, April 15th. They issued a “buy” rating and a $100.00 price objective for the company. Barrington Research set a $97.00 price objective on shares of Henry Schein and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Mizuho increased their price objective on shares of Henry Schein from $81.00 to $88.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Finally, Robert W. Baird set a $100.00 price objective on shares of Henry Schein and gave the company an “outperform” rating in a research report on Monday, February 23rd. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Henry Schein currently has an average rating of “Hold” and a consensus target price of $87.75.

Henry Schein Stock Up 1.6%

Shares of HSIC stock traded up $1.15 during mid-day trading on Tuesday, reaching $73.17. 642,816 shares of the company were exchanged, compared to its average volume of 1,296,928. Henry Schein has a fifty-two week low of $61.94 and a fifty-two week high of $89.29. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.38. The company has a market capitalization of $8.40 billion, a P/E ratio of 22.35, a P/E/G ratio of 2.19 and a beta of 0.82. The business’s 50 day simple moving average is $76.59 and its 200 day simple moving average is $74.85.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. During the same quarter in the prior year, the company earned $1.15 earnings per share. Henry Schein’s quarterly revenue was up 6.3% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Research analysts predict that Henry Schein will post 5.3 earnings per share for the current year.

Insiders Place Their Bets

In other Henry Schein news, Director Kurt P. Kuehn sold 2,844 shares of Henry Schein stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total value of $224,562.24. Following the completion of the transaction, the director owned 15,420 shares of the company’s stock, valued at $1,217,563.20. The trade was a 15.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Stanley M. Bergman sold 43,812 shares of Henry Schein stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $81.31, for a total transaction of $3,562,353.72. Following the completion of the transaction, the chief executive officer directly owned 383,803 shares of the company’s stock, valued at approximately $31,207,021.93. This represents a 10.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 105,911 shares of company stock valued at $8,574,982. 0.89% of the stock is owned by company insiders.

Key Stories Impacting Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q1 results topped estimates — EPS $1.32 vs. $1.20 consensus, revenue up ~6.3% year-over-year, and gross margins improved, driven by strong segment performance and market-share gains. HSIC Q1 Earnings & Revenues Surpass Estimates, Gross Margin Rises
• Positive Sentiment: Company press release reiterates momentum from late 2025, noting market-share gains and progress on value-creation initiatives that management cites as supporting longer-term growth. Henry Schein Reports First Quarter 2026 Financial Results
• Positive Sentiment: Management reaffirmed its FY 2026 profit outlook after the beat and highlighted continued strength in the dental business — a sign of execution that supports investor confidence. Henry Schein reaffirms annual profit forecast, beats Q1 estimates on dental strength
• Neutral Sentiment: FY 2026 guidance provided: EPS range $5.230–$5.370 and revenue $13.6B–$13.8B — roughly in line with consensus but the EPS range slightly brackets Street estimates, leaving some room for interpretation on upside. (Guidance detail released by the company.)
• Neutral Sentiment: Company posted investor materials and a conference-call transcript/slide deck for Q1 — useful for investors wanting detail on segment trends and margin drivers. Q1 press materials and slide deck
• Negative Sentiment: One data-piece noted recent underperformance versus peers on a specific trading day, a reminder that stock can lag sector moves even when company fundamentals are positive. Henry Schein Inc. stock underperforms Monday when compared to competitors

Hedge Funds Weigh In On Henry Schein

A number of hedge funds and other institutional investors have recently bought and sold shares of HSIC. Intech Investment Management LLC acquired a new position in shares of Henry Schein during the fourth quarter valued at $525,000. &PARTNERS acquired a new position in shares of Henry Schein during the fourth quarter valued at $488,000. Tower Research Capital LLC TRC boosted its holdings in shares of Henry Schein by 291.1% during the third quarter. Tower Research Capital LLC TRC now owns 7,352 shares of the company’s stock valued at $488,000 after acquiring an additional 5,472 shares during the period. Vident Advisory LLC boosted its holdings in shares of Henry Schein by 25.6% during the second quarter. Vident Advisory LLC now owns 6,429 shares of the company’s stock valued at $470,000 after acquiring an additional 1,309 shares during the period. Finally, Cetera Investment Advisers boosted its holdings in shares of Henry Schein by 12.9% during the second quarter. Cetera Investment Advisers now owns 5,561 shares of the company’s stock valued at $406,000 after acquiring an additional 637 shares during the period. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.